|
1
|
Yao FY, Hirose R, LaBerge JM, Davern TJ
III, Bass NM, Kerlan RK Jr, Merriman R, Feng S, Freise CE, Ascher
NL, et al: A prospective study on downstaging of hepatocellular
carcinoma prior to liver transplantation. Liver Transpl.
11:1505–1514. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mazzaferro V, Regalia E, Doci R, Andreola
S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and
Gennari L: Liver transplantation for the treatment of small
hepatocellular carcinomas in patients with cirrhosis. N Engl J Med.
334:693–699. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yao FY, Xiao L, Bass NM, Kerlan R, Ascher
NL and Roberts JP: Liver transplantation for hepatocellular
carcinoma: Validation of the UCSF-expanded criteria based on
preoperative imaging. Am J Transplant. 7:2587–2596. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shin WY, Suh KS, Lee HW, Kim J, Kim T, Yi
NJ and Lee KU: Prognostic factors affecting survival after
recurrence in adult living donor liver transplantation for
hepatocellular carcinoma. Liver Transpl. 16:678–684. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okuno T, Tsuruyama T, Haga H, Ueda M,
Takada Y, Maetani Y, Manabe T and Tamaki K: A comparative study of
pathological staging systems in predicting recurrent hepatocellular
carcinoma after liver transplantation. J Hepatobiliary Pancreat
Surg. 16:802–807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen J, Xu X, Wu J, Ling Q, Wang K, Wang
W, Zhang M, Shen Y, Zhou L, Xie H, et al: The stratifying value of
Hangzhou criteria in liver transplantation for hepatocellular
carcinoma. PLoS One. 9:e931282014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rodríguez-Perálvarez M, Luong TV, Andreana
L, Meyer T, Dhillon AP and Burroughs AK: A systematic review of
microvascular invasion in hepatocellular carcinoma: Diagnostic and
prognostic variability. Ann Surg Oncol. 20:325–339. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pawlik TM, Gleisner AL, Anders RA,
Assumpcao L, Maley W and Choti MA: Preoperative assessment of
hepatocellular carcinoma tumor grade using needle biopsy:
Implications for transplant eligibility. Ann Surg. 245:435–442.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee JW, Hwang SH, Kim HJ, Kim D, Cho A and
Yun M: Volumetric parameters on FDG PET can predict early
intrahepatic recurrence-free survival in patients with
hepatocellular carcinoma after curative surgical resection. Eur J
Nucl Med Mol Imaging. 44:1984–1994. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB
and Kao CH: 18F-FDG PET or PET/CT for detecting
extrahepatic metastases or recurrent hepatocellular carcinoma: A
systematic review and meta-analysis. Eur J Radiol. 81:2417–2422.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee JW, Yun M, Cho A, Han KH, Kim DY, Lee
SM and Lee JD: The predictive value of metabolic tumor volume on
FDG PET/CT for transarterial chemoembolization and transarterial
chemotherapy infusion in hepatocellular carcinoma patients without
extrahepatic metastasis. Ann Nucl Med. 29:400–408. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim YI, Paeng JC, Cheon GJ, Suh KS, Lee
DS, Chung JK and Kang KW: Prediction of Posttransplantation
Recurrence of Hepatocellular Carcinoma Using Metabolic and
Volumetric Indices of 18F-FDG PET/CT. J Nucl Med.
57:1045–1051. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hwang SH, Lee JW, Cho HJ, Kim KS, Choi GH
and Yun M: Prognostic Value of Metabolic Tumor Volume and Total
Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With
Very Early and Early Hepatocellular Carcinoma. Clin Nucl Med.
42:34–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moon SH, Hyun SH and Choi JY: Prognostic
significance of volume-based PET parameters in cancer patients.
Korean J Radiol. 14:1–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Esfahani SA, Heidari P, Halpern EF,
Hochberg EP, Palmer EL and Mahmood U: Baseline total lesion
glycolysis measured with (18)F-FDG PET/CT as a predictor of
progression-free survival in diffuse large B-cell lymphoma: A pilot
study. Am J Nucl Med Mol Imaging. 3:272–281. 2013. View Article : Google Scholar : PubMed/NCBIPubMed/NCBI
|
|
16
|
Meignan M, Gallamini A, Meignan M,
Gallamini A and Haioun C: Report on the First International
Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma.
50:1257–1260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mazzaferro V, Llovet JM, Miceli R, Bhoori
S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi
GL, et al Metroticket Investigator Study Group, : Predicting
survival after liver transplantation in patients with
hepatocellular carcinoma beyond the Milan criteria: A
retrospective, exploratory analysis. Lancet Oncol. 10:35–43. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kornberg A, Witt U, Schernhammer M,
Kornberg J, Ceyhan GO, Mueller K, Friess H and Thrum K: Combining
18F-FDG positron emission tomography with Up-to-seven
criteria for selecting suitable liver transplant patients with
advanced hepatocellular carcinoma. Sci Rep. 7:141762017.
|
|
19
|
Kornberg A, Schernhammer M and Friess H:
18F-FDG-PET for Assessing Biological Viability and Prognosis in
Liver Transplant Patients with Hepatocellular Carcinoma. J Clin
Transl Hepatol. 5:224–234. 2017.PubMed/NCBI
|
|
20
|
Yao FY, Ferrell L, Bass NM, Watson JJ,
Bacchetti P, Venook A, Ascher NL and Roberts JP: Liver
transplantation for hepatocellular carcinoma: Expansion of the
tumor size limits does not adversely impact survival. Hepatology.
33:1394–1403. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng SS, Xu X, Wu J, Chen J, Wang WL,
Zhang M, Liang TB and Wu LM: Liver transplantation for
hepatocellular carcinoma: Hangzhou experiences. Transplantation.
85:1726–1732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ahn SG, Kim SH, Jeon TJ, Cho HJ, Choi SB,
Yun MJ, Lee JD and Kim KS: The role of preoperative
[18F]fluorodeoxyglucose positron emission tomography in predicting
early recurrence after curative resection of hepatocellular
carcinomas. J Gastrointest Surg. 15:2044–2052. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Shi ZL, Yang X and Yin ZF:
Targeting of circulating hepatocellular carcinoma cells to prevent
postoperative recurrence and metastasis. World J Gastroenterol.
20:142–147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prasad KR, Young RS, Burra P, Zheng SS,
Mazzaferro V, Moon DB and Freeman RB: Summary of candidate
selection and expanded criteria for liver transplantation for
hepatocellular carcinoma: A review and consensus statement. Liver
Transpl. 17 (Suppl 2):S81–S89. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Figueras J, Ibañez L, Ramos E, Jaurrieta
E, Ortiz-de-Urbina J, Pardo F, Mir J, Loinaz C, Herrera L,
López-Cillero P, et al: Selection criteria for liver
transplantation in early-stage hepatocellular carcinoma with
cirrhosis: Results of a multicenter study. Liver Transpl.
7:877–883. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ye YF, Wang W, Wang T, Yu J, Geng L, Yu
SF, Yan S and Zheng SS: Role of 18F fludeoxyglucose
positron emission tomography in the selection of liver
transplantation candidates in patients with hepatocellular
carcinoma. Hepatobiliary Pancreat Dis Int. 16:257–263. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao
L, Morris JS, Macapinlac HA, Hassan MM and Kaseb AO: Refining
prognosis in patients with hepatocellular carcinoma through
incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol
Imaging Jun. 44:969–978. 2017. View Article : Google Scholar
|
|
28
|
Yamamoto Y, Nishiyama Y, Kameyama R, Okano
K, Kashiwagi H, Deguchi A, Kaji M and Ohkawa M: Detection of
hepatocellular carcinoma using 11C-choline PET: Comparison with
18F-FDG PET. J Nucl Med. 49:1245–1248. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bertagna F, Bertoli M, Bosio G, Biasiotto
G, Sadeghi R, Giubbini R and Treglia G: Diagnostic role of
radiolabelled choline PET or PET/CT in hepatocellular carcinoma: A
systematic review and meta-analysis. Hepatol Int. 8:493–500. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Castilla-Lièvre MA, Franco D, Gervais P,
Kuhnast B, Agostini H, Marthey L, Désarnaud S and Helal BO:
Diagnostic value of combining 11C-choline and
18F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl
Med Mol Imaging. 43:852–859. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JD, Yang WI, Park YN, Kim KS, Choi JS,
Yun M, Ko D, Kim TS, Cho AE, Kim HM, et al: Different glucose
uptake and glycolytic mechanisms between hepatocellular carcinoma
and intrahepatic mass-forming cholangiocarcinoma with increased
(18)F-FDG uptake. J Nucl Med. 46:1753–1759. 2005.PubMed/NCBI
|
|
32
|
Seo S, Hatano E, Higashi T, Nakajima A,
Nakamoto Y, Tada M, Tamaki N, Iwaisako K, Kitamura K, Ikai I, et
al: P-glycoprotein expression affects
18F-fluorodeoxyglucose accumulation in hepatocellular
carcinoma in vivo and in vitro. Int J Oncol. 34:1303–1312.
2009.PubMed/NCBI
|
|
33
|
Pant V, Sen IB and Soin AS: Role of
18F-FDG PET CT as an independent prognostic indicator in
patients with hepatocellular carcinoma. Nucl Med Commun.
34:749–757. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee SD, Kim SH, Lee EC, Park S-J, Kim YK,
Han SS and Park HM: Expanded selection criteria of living donor
liver transplantation for hepatocellular carcinoma using total
tumor size and 18 F-FDG-PET/CT. HPB (Oxford). 18:e192016.
View Article : Google Scholar
|
|
35
|
Hong CM, Ahn BC, Jang YJ, Jeong SY, Lee SW
and Lee J: Prognostic Value of Metabolic Parameters of
18F-FDG PET/CT and Apparent Diffusion Coefficient of MRI
in Hepatocellular Carcinoma. Clin Nucl Med. 42:95–99. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin CY, Liao CW, Chu LY, Yen KY, Jeng LB,
Hsu CN, Lin CL and Kao CH: Predictive Value of 18F-FDG
PET/CT for Vascular Invasion in Patients With Hepatocellular
Carcinoma Before Liver Transplantation. Clin Nucl Med.
42:e183–e187. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ahn SY, Lee JM, Joo I, Lee ES, Lee SJ,
Cheon GJ, Han JK and Choi BI: Prediction of microvascular invasion
of hepatocellular carcinoma using gadoxetic acid-enhanced MR and
(18)F-FDG PET/CT. Abdom Imaging. 40:843–851. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Asman Y, Evenson AR, Even-Sapir E and
Shibolet O: [18F]fludeoxyglucose positron emission tomography and
computed tomography as a prognostic tool before liver
transplantation, resection, and loco-ablative therapies for
hepatocellular carcinoma. Liver Transpl. 21:572–580. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee SD, Kim SH, Kim YK, Kim C, Kim SK, Han
SS and Park SJ: (18)F-FDG-PET/CT predicts early tumor recurrence in
living donor liver transplantation for hepatocellular carcinoma.
Transpl Int. 26:50–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ochi H, Hirooka M, Hiraoka A, Koizumi Y,
Abe M, Sogabe I, Ishimaru Y, Furuya K, Miyagawa M, Kawasaki H, et
al: 18F-FDG-PET/CT predicts the distribution of
microsatellite lesions in hepatocellular carcinoma. Mol Clin Oncol.
2:798–804. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kitamura K, Hatano E, Higashi T, Seo S,
Nakamoto Y, Yamanaka K, Iida T, Taura K, Yasuchika K and Uemoto S:
Preoperative FDG-PET predicts recurrence patterns in hepatocellular
carcinoma. Ann Surg Oncol. 19:156–162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cascales-Campos PA, Ramírez P, Lopez V,
Gonzalez R, Saenz-Mateos L, Llacer E, Sánchez Bueno F, Robles R,
Pons JA, Capel A, et al: Prognostic value of
18-Fluorodeoxyglucose-positron emission tomography after
transarterial chemoembolization in patients with hepatocellular
carcinoma undergoing orthotopic liver transplantation. Transplant
Proc. 47:2374–2376. 2015. View Article : Google Scholar : PubMed/NCBI
|
